Table 2 Summary of patient characteristics.
Characteristics of cohort | ||||
Mean age at diagnosis (range, SD) | 61 years (28–94, 15.2) | |||
Median visual acuity at diagnosis logMAR (range, IQR) | OD | OS | ||
0.10 (−0.1 to 1, 0 to 0.27) | 0.10 (−0.20 to 1.8, 0 to 0.29) | P = 0.29 | ||
Median 10-2 Humphrey visual field MD (dB) (range, IQR) | −4.8 dB (−29.96 dB to −0.05 dB, −10.39 dB to −2.42 dB) | −3.92 dB (−29.30 dB to 1.30 dB, −8.95 dB to −2.22 dB) | P = 0.71 | |
Disease distribution | Parafoveal | Pericentral | Mixed | |
50 | 6 | 7 | ||
Median daily dose, mg (range, IQR) | 350 mg (66–400 mg, 200–400 mg) | |||
Median duration of drug use (range, IQR) | 12 years, 1 month (4 months to 50 years, 9 years 1.5 months to 20 years) | |||
ELM disruption on OCT imaging | 63% | |||
Comparison of symptomatic and asymptomatic patients | ||||
Symptomatic | Asymptomatic | |||
Number | 27 | 43 | ||
Mean age, years (range, SD) | 60.5 years (14.7 years, 30–82 years) | 61.8 years (15.4 years, 28–94 years) | P = 0.73 | |
Median duration of drug use, years (range, IQR) | 12 years (3 years to 25 years, 8 years 0.75 months to 20 years) | 13 years (4 months to 50 years, 9 years 9 months to 20 years) | P = 0.33 | |
Median daily dose, mg (range, IQR) | 400 mg (200–400 mg, 200–400 mg) | 250 mg (66–400 mg, 200–400 mg) | P = 0.43 | |
Median VA of worst seeing eye logMAR (range, IQR) | 0.22 (−0.10 to 1.80, 0.06 to 0.50) | 0.10 (−0.10 to 0.68, 0.00 to 0.17) | P = 0.007 | |
Median 10-2 field deficit of worst seeing eye (dB) (range, IQR) | −8.70 dB (−29.96 dB to −3.15 dB, −18.78 dB to −6.20 dB) | −3.73 dB (−27.04 dB to −1.81 dB, −9.36 dB to −2.29 dB) | P = 0.017 | |
Disease distribution | ||||
Parafoveal | 73% | 87% | ||
Pericentral | 9% | 11% | ||
Mixed | 18% | 3% | ||
ELM disruption on OCT imaging | 67% | 53% | P = 0.18 | |
Comparison of patients based on ELM status on OCT at diagnosis | ||||
ELM disruption at diagnosis | ELM preserved at diagnosis | |||
Number | 45 | 26 | ||
Mean age in years (SD, range) | 61.5 years (16.2 years, 28–94 years) | 59.9 years (13.5 years, 30–88 years) | P = 0.67 | |
Median VA of worst seeing eye, logMAR (range, IQR) | 0.17 (−0.10 to 1.80, 0.08 to 0.32) | 0.10 (−0.10–0.50, 0.00 to 0.17) | P = 0.03 | |
Median field deficit of worst seeing eye (dB) (range, IQR) | −8.95 dB (−29.96 dB to −0.82 dB, −18.15 dB to −3.92 dB) | −3.67 dB (−20.67 dB to −0.05 dB, −6.96 dB to −2.75 dB) | P = 0.02 | |
Symptoms at diagnosis | 44% | 31% | P = 0.33 | |
Median duration of drug use in years (range, IQR) | 14 years, 6 months (5 years to 50 years, 10 years to 20 years) | 10 years, 6 months (4 months to 40 years, 8 years to 16 years 3 months) | P = 0.16 | |
Median daily dose, mg (range, IQR) | 400 mg (200–400 mg, 200–400 mg) | 200 mg (66–400 mg, 200–400 mg) | P = 0.44 | |
